Less than 20% of people in Japan who showed interest in new medications for Alzheimer's disease went on to receive one, mainly because they were not medically eligible or they decided against it for fear of side effects. https://www.japantimes.co.jp/news/2026/04/08/japan/science-health/dementia-drugs-research/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimers #lecanemab #donanemab #health #medicine #dementia #brain